US 12,186,332 B2
Methods for overcoming WNT/beta-catenin anti-cancer resistance in leukemia stem cells
Linheng Li, Kansas City, MO (US); John M. Perry, Olathe, KS (US); Fang Tao, Overland Park, KS (US); Xi C. He, Kansas City, MO (US); Anuradha Roy, Kansas City, MO (US); Scott J. Weir, Overland Park, KS (US); and Tara Lin, Mission Hills, KS (US)
Assigned to Stowers Institute for Medical Research, Kansas City, KS (US); The Children's Mercy Hospital, Kansas City, KS (US); and University of Kansas, Lawrence, KS (US)
Filed by STOWERS INSTITUTE FOR MEDICAL RESEARCH, Kansas City, MO (US); THE CHILDREN'S MERCY HOSPITAL, Kansas City, MO (US); and UNIVERSITY OF KANSAS, Lawrence, KS (US)
Filed on Jun. 26, 2020, as Appl. No. 16/914,086.
Claims priority of provisional application 62/867,780, filed on Jun. 27, 2019.
Prior Publication US 2021/0113597 A1, Apr. 22, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/704 (2006.01); A61K 39/395 (2006.01); A61P 35/02 (2006.01); C07K 16/28 (2006.01)
CPC A61K 31/704 (2013.01) [A61K 39/3955 (2013.01); A61P 35/02 (2018.01); C07K 16/2818 (2013.01)] 10 Claims
 
1. A method for treating or ameliorating the effects of a cancer in a human subject comprising administering to the subject a first agent, which is daunorubicin or pharmaceutically acceptable salt thereof, and a therapeutically effective amount of a second agent, which is a chemotherapeutic,
wherein daunorubicin is administered at 6.75 mg/m2 daily, for 5 consecutive days.